Neutrophil-lymphocyte and platelet-lymphocyte ratios for assessing disease activity in patients with rheumatoid arthritis receiving tofacitinib treatment.
10.12122/j.issn.1673-4254.2023.10.01
- Author:
Juan TANG
1
;
Juan CHEN
1
;
Guoxin LIN
2
;
Hao ZHANG
1
;
Ming GUI
1
;
Nannan LI
1
;
Yihong GU
1
;
Linjuan LUO
1
;
Jian SUN
1
Author Information
1. Department of Nephrology and Rheumatology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
2. Department of Anesthesiology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
- Publication Type:Journal Article
- Keywords:
neutrophil-lymphocyte ratio;
platelet-lymphocyte ratio;
rheumatoid arthritis;
tofacitinib
- MeSH:
Humans;
Neutrophils;
Retrospective Studies;
C-Reactive Protein/analysis*;
Interleukin-6/metabolism*;
Arthritis, Rheumatoid;
Lymphocytes
- From:
Journal of Southern Medical University
2023;43(10):1651-1656
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the value of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for assessing disease activity in patients with rheumatoid arthritis (RA) treated with tofacitinib.
METHODS:This retrospective study was conducted among 98 RA patients in active stage treated with tofacitinib in Third Xiangya Hospital and 100 healthy control subjects from the Health Management Center of the hospital from 2019 to 2021. We collected blood samples from all the participants for measurement of erythrocyte sedimentation rate (ESR), high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6) and other blood parameters 1 month before and 6 months after tofacitinib treatment. We further evaluated PLR and NLR before and after tofacitinib treatment in the RA patients, and analyzed their correlations with RA disease activity.
RESULTS:PLR and NLR increased significantly in RA patients as compared with the healthy controls. In the RA patients, PLR and NLR were positively correlated with the levels of hs- CRP, ESR, IL- 6, Disease Activity Score of 28 joints-ESR (DAS28-ESR), anti-cyclic citrullinated peptide (CCP), and rheumatoid factor (RF) before and after tofacitinib treatment. Tofacitinib treatment for 6 months significantly decreased hs-CRP, ESR, IL-6, CCP, RF and DAS28-ESR levels in the RA patients.
CONCLUSION:NLR and PLR can be useful biomarkers for assessing disease activity in RA patients treated with tofacitinib.
